Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - October 2012


Models of experimental pain: opportunities and challenges

11 Oct 2012 - 11 Oct 2012 - London, UK



Bookmark and Share


The NC3Rs, the British Pharmacological Society and the Physiological Society are hosting a joint symposium in central London on 11 October 2012 to discuss opportunities for developing new and better models of experimental pain, with reduced reliance on animal models.

Programme
The meeting will be chaired by Professor Stephen McMahon, King's College London, and confirmed speakers include:

    Professor Andrew Rice, Imperial College London
    Neuropathic pain: Refinement and enhancing the clinical relevance of rodent in vivo models
    Dr Nick Andrews, Harvard Medical School
    From reflex to voluntary assays: can we improved clinical translation of analgesics?
    Dr David Borsook, Harvard Medical School
    Imaging across analgesic drug development: A missing link?
    Professor Paul Flecknell, Newcastle University
    Pain or nociception what do our animals model?
    Dr Emily Sena, University of Edinburgh
    Systematic review and meta-analysis to improve animal models of pain.
    Dr Nathalie Percie du Sert, NC3Rs
    The ARRIVE guidelines
    Dr Lynne Sneddon, University of Liverpool
    Exploring the use of fish as models of nociception
    Dr Sean Sweeney, University of York
    Using Drosophila nociceptive responses to model sensory neuropathy
    Dr Kathryn Chapman, NC3Rs
    Using CRACK IT to generate new models of experimental pain
    Dr Mohammed Nassar, University of Sheffield
    Derivation of conditionally immortalised mouse DRG cell lines
    Dr James Bisland, Pfizer Neusentis
    Functional characterisation of human pluripotent stem cell derived sensory neurones



Further information
Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!